About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CASI
- Previous Close: $1.41
- 50 Day Moving Average: $1.31
- 200 Day Moving Average: $1.28
- 52-Week Range: $0.78 - $1.76
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.88
- P/E Growth: 0.00
- Market Cap: $84.88M
- Outstanding Shares: 60,196,000
- Beta: 0.76
- Return on Equity: -137.98%
- Return on Assets: -52.97%
Companies Related to CASI Pharmaceuticals:
- Current Ratio: 9.58%
- Quick Ratio: 9.58%
What is CASI Pharmaceuticals' stock symbol?
CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."
Where is CASI Pharmaceuticals' stock going? Where will CASI Pharmaceuticals' stock price be in 2017?
2 analysts have issued twelve-month price targets for CASI Pharmaceuticals' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $4.00 in the next twelve months.
When will CASI Pharmaceuticals announce their earnings?
CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.
Who owns CASI Pharmaceuticals stock?
CASI Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.21%). Company insiders that own CASI Pharmaceuticals stock include Byte Ltd Sparkle, China Growth Fund Idg-Accel II, Cynthia W Hu, Ken Ren, Spectrum Pharmaceuticals Inc and Wei-Wu He.
Who bought CASI Pharmaceuticals stock? Who is buying CASI Pharmaceuticals stock?
CASI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Byte Ltd Sparkle, China Growth Fund Idg-Accel II, Cynthia W Hu, Ken Ren, Spectrum Pharmaceuticals Inc and Wei-Wu He.
How do I buy CASI Pharmaceuticals stock?
Shares of CASI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CASI Pharmaceuticals stock cost?
One share of CASI Pharmaceuticals stock can currently be purchased for approximately $1.41.